Request for Covid-19 Impact Assessment of this Report

Take Action
Healthcare

Global Biosimilar Monoclonal Antibody Market Size study, by Type (Synthetic Chemicals, Biopharmaceuticals and Others), By Application (Chronic & Autoimmune Diseases, Oncology and Others) and Regional Forecasts 2019-2026

  • BIZ3808003
  • 200 Pages
  • April 2020
  • Healthcare
Download Sample    Get Discount   
 
Global Biosimilar Monoclonal Antibody Market is valued approximately at USD 27.84 Billion in 2018 and is anticipated to grow with a healthy growth rate of more than 35.70% over the forecast period 2019-2026. Biosimilar monoclonal antibodies can be known as a biological molecule derived by the organisms and living cells. Also, it displays a certain level of variability which can be attributed to the variations in the biological expression systems of the recombinant. In addition, biosimilar monoclonal antibodies are widely used in various fields of diagnostics of diseases such as oncology, autoimmune and in various chronic diseases. The Biosimilar Monoclonal Antibody market to witness prominent growth owing to the incorporation of advanced mAbs (Monoclonal Antibodies). As a result, the demand & adoption for Biosimilar Monoclonal Antibody would increase thereby, making its way for the growth of the market. The growth of the market is primarily driven by the increase in prevalence of diseases, such as cancer and rheumatoid arthritis and growth in geriatric population globally. For Instance: according to World Cancer Research Fund International (WCRFI), breast cancer is the most common form of cancer in women worldwide with an average 2million new cases being detected every year. American Cancer Research Society (ACRS) anticipates by 2030, incident rate of breast cancer is expected to reach over 9.9million cases with over 5.5million annual deaths, primarily due to aging population. Similarly, as per the European Breast Cancer Coalition, incidence in the EU-28 in 2018 was estimated to be around 404,920. Thus, the demand for biosimilar monoclonal antibodies would increase as these drugs are normally administered in the treatment of cancer, chronic lymphocytic and leukemia. However, unfavorable government regulations in developed regions along with the high cost associated with the manufacturing process of these drugs are expected to impede the growth of the market over the forecast period.

The regional analysis of global Biosimilar Monoclonal Antibody market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is expected to hold a notable share in the world in terms of revenue owing to the presence of advanced healthcare facilities along with the increasing adoption of biosimilar monoclonal antibodies. The dominance of the region is witnessed owing to the ongoing government activities to develop advanced and novel drugs. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period. Factors such as rising public-private initiative aimed towards boosting advance research practices and increase investment to promote Biosimilar Monoclonal Antibody research is expected to create lucrative prospects for the growth pf the region during the forecast period of 2019-2026.

Major market player included in this report are:

Allergan plc

BIOCAD BioXpress

Therapeutics SA

Biocon Limited

Boehringer Ingelheim GmbH

Celltrion Inc

Coherus BioSciences Inc

Dr. Reddys Laboratories Ltd

Genor BioPharma Co Ltd

Intas Pharmaceuticals Limited

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Synthetic Chemicals

Biopharmaceuticals

Others

By Application:

Chronic & Autoimmune Diseases

Oncology

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

Asia Pacific

China

India

Japan

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017

Base year – 2018

Forecast period – 2019 to 2026

Target Audience of the Global Biosimilar Monoclonal Antibody Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

1.1. Market Snapshot

1.2. Global & Segmental Market Estimates & Forecasts, 2017-2026 (USD Billion)

1.2.1. Biosimilar Monoclonal Antibody Market, by Region, 2017-2026 (USD Billion)

1.2.2. Biosimilar Monoclonal Antibody Market, by Type, 2017-2026 (USD Billion)

1.2.3. Biosimilar Monoclonal Antibody Market, by Application, 2017-2026 (USD Billion)

1.2.4. Biosimilar Monoclonal Antibody Market, by End-User, 2017-2026 (USD Billion)

1.3. Key Trends

1.4. Estimation Methodology

1.5. Research Assumption

Chapter 2. Global Biosimilar Monoclonal Antibody Market Definition and Scope

2.1. Objective of the Study

2.2. Market Definition & Scope

2.2.1. Scope of the Study

2.2.2. Industry Evolution

2.3. Years Considered for the Study

2.4. Currency Conversion Rates

Chapter 3. Global Biosimilar Monoclonal Antibody Market Dynamics

3.1. Biosimilar Monoclonal Antibody Market Impact Analysis (2018-2026)

3.1.1. Market Drivers

3.1.2. Market Challenges

3.1.3. Market Opportunities

Chapter 4. Global Biosimilar Monoclonal Antibody Market: Industry Analysis

4.1. Porter’s 5 Force Model

4.1.1. Bargaining Power of Suppliers

4.1.2. Bargaining Power of Buyers

4.1.3. Threat of New Entrants

4.1.4. Threat of Substitutes

4.1.5. Competitive Rivalry

4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)

4.2. PEST Analysis

4.2.1. Political

4.2.2. Economical

4.2.3. Social

4.2.4. Technological

4.3. Investment Adoption Model

4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Biosimilar Monoclonal Antibody Market, by Type

5.1. Market Snapshot

5.2. Global Biosimilar Monoclonal Antibody Market by Type, Performance - Potential Analysis

5.3. Global Biosimilar Monoclonal Antibody Market Estimates & Forecasts by Type, 2016-2026 (USD Billion)

5.4. Biosimilar Monoclonal Antibody Market, Sub Segment Analysis

5.4.1. Synthetic Chemicals

5.4.2. Biopharmaceuticals

5.4.3. Others

Chapter 6. Global Biosimilar Monoclonal Antibody Market, by Application

6.1. Market Snapshot

6.2. Global Biosimilar Monoclonal Antibody Market by Application, Performance - Potential Analysis

6.3. Global Biosimilar Monoclonal Antibody Market Estimates & Forecasts by Application 2016-2026 (USD Billion)

6.4. Biosimilar Monoclonal Antibody Market, Sub Segment Analysis

6.4.1. Chronic & Autoimmune Diseases

6.4.2. Oncology

6.4.3. Others

Chapter 7. Global Biosimilar Monoclonal Antibody Market, Regional Analysis

7.1. Biosimilar Monoclonal Antibody Market, Regional Market Snapshot

7.2. North America Biosimilar Monoclonal Antibody Market

7.2.1. U.S. Biosimilar Monoclonal Antibody Market

7.2.1.1. Type breakdown estimates & forecasts, 2016-2026

7.2.1.2. Application Industry breakdown estimates & forecasts, 2016-2026

7.2.2. Canada Biosimilar Monoclonal Antibody Market

7.3. Europe Biosimilar Monoclonal Antibody Market Snapshot

7.3.1. U.K. Biosimilar Monoclonal Antibody Market

7.3.2. Germany Biosimilar Monoclonal Antibody Market

7.3.3. Rest of Europe Biosimilar Monoclonal Antibody Market

7.4. Asia-Pacific Biosimilar Monoclonal Antibody Market Snapshot

7.4.1. China Biosimilar Monoclonal Antibody Market

7.4.2. India Biosimilar Monoclonal Antibody Market

7.4.3. Japan Biosimilar Monoclonal Antibody Market

7.4.4. Rest of Asia Pacific Biosimilar Monoclonal Antibody Market

7.5. Latin America Biosimilar Monoclonal Antibody Market Snapshot

7.5.1. Brazil Biosimilar Monoclonal Antibody Market

7.5.2. Mexico Biosimilar Monoclonal Antibody Market

7.6. Rest of The World Biosimilar Monoclonal Antibody Market

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies

8.2. Company Profiles

8.2.1. Allergan plc

8.2.1.1. Key Information

8.2.1.2. Overview

8.2.1.3. Financial (Subject to Data Availability)

8.2.1.4. Product Summary

8.2.1.5. Recent Developments

8.2.2. BIOCAD BioXpress

8.2.3. Therapeutics SA,

8.2.4. Biocon Limited

8.2.5. Boehringer Ingelheim GmbH

8.2.6. Celltrion Inc

8.2.7. Coherus BioSciences Inc

8.2.8. Dr. Reddys Laboratories Ltd

8.2.9. Genor BioPharma Co Ltd

8.2.10. Intas Pharmaceuticals Limited

Chapter 9. Research Process

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

9.3. Research Assumption

TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET

TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET

TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, REPORT SCOPE

TABLE 4. YEARS CONSIDERED FOR THE STUDY

TABLE 5. EXCHANGE RATES CONSIDERED

TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)

TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY TYPE 2016-2026 (USD BILLION)

TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY APPLICATION 2016-2026 (USD BILLION)

TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY END-USER 2016-2026 (USD BILLION)

TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 21. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 22. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 23. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 24. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 25. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 26. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 27. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 28. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 29. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 30. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 31. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 32. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 33. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 34. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 35. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 36. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 37. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 38. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 39. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 40. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 41. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 42. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 43. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 44. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 45. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 46. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 47. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 48. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 49. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 50. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 51. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 52. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 53. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 54. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 55. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 56. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 57. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 58. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 59. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 63. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 64. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 65. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 66. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 67. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 68. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)

TABLE 69. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 70. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

TABLE 71. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

2020 World Blood Typing, Grouping and Infectious Disease NAT Screening Market in 68 Countries: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for over 40 Tests, Technology and Instrumentation Review

This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.

The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...

  • Publish Date: March 2, 2020
  • $0
View Details
Hearing Aids Market in India 2011

Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...

  • Publish Date: March 10, 2011
  • $950
View Details
Cardiac Pacemaker Market in India 2011

The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...

  • Publish Date: July 18, 2011
  • $950
View Details
 
View More
 

Client Testimonials

2026 © Copyright Big Market Research